Protalix BioTherapeutics, Inc. (PLX)

2.0000 +0.0600 (+3.09%) As of 01:59PM EDT. Market open.

Protalix BioTherapeutics, Inc.

2 University Plaza
Suite 100
Hackensack, NJ 07601
United States
201 696 9345
https://www.protalix.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 193

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Dror Bashan	Pres, CEO & Director	490.1k	N/A	1967
Mr. Eyal Rubin M.B.A.	Sr. VP, CFO, Treasurer & Corp. Sec.	430.56k	N/A	1976
Mr. Yaron Naos	Sr. VP of Operations	N/A	N/A	1964
Ms. Yael Fellous	VP of HR	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Corporate Governance

Protalix BioTherapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.